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Abstract
Background:  Identification and adequate management of individuals at risk for hereditary
nonpolyposis colorectal cancer (HNPCC) is crucial since surveillance programmes reduce
morbidity and mortality. We investigated knowledge about key features of HNPCC in at risk
individuals and physicians in surgery, gynecology and oncology.
Methods: Data were collected using a questionnaire which was answered by 67 mutation carriers
and 102 physicians from the southern Swedish health care region. The statements were related to
colorectal cancer, heredity and surveillance and the physicians were also asked questions about
cancer risks and surveillance strategies.
Results: Both groups answered questions on colorectal cancer risk, surveillance and genetic
testing well, whereas answers about inheritance and risks for HNPCC associated cancer were less
accurate. Only half of the family members and one third of the physicians correctly estimated the
risk to inherit an HNPCC predisposing mutation. Among family members, young age (<57 years),
female sex and recent genetic counseling significantly correlated with better results. Physicians
generally underestimated the risk of HNPCC associated cancers and three out of four suggested a
later starting age for surveillance than recommended.
Conclusion: The finding of similar levels of knowledge about key features of HNPCC in at risk
individuals and physicians reflect the challenge physicians face in keeping up to date on hereditary
cancer and may have implications for the clinical management and professional relations with
HNPCC family members.
Background
Clinicians are increasingly expected to be familiar with
hereditary cancer, including diagnostic criteria, the genetic
testing process and recommendations for surveillance and
surgery. Though physicians cannot be expected to have
detailed knowledge of causative genes and testing plat-
forms, it remains their responsibility to identify at risk
individuals and recommend appropriate surveillance.
Strategies here for have been adopted by several medical
societies and are of particular relevance for physicians in
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primary health care, surgery, gynecology and oncology [1-
6]. At the same time, members in families with hereditary
cancer are increasingly well informed through various
educational programmes, printed information, internet
sites and a growing number of patient associations.
Knowledge about hereditary cancer is central and has
been demonstrated to correlate with participation in sur-
veillance programmes [1,7,8].
Hereditary nonpolyposis colorectal cancer (HNPCC) is
the most common form of hereditary colon cancer with
an estimated prevalence of 1/2000 [9]. Colorectal cancer
predominates with a life time risk of 60–90%, but female
mutation carriers are also at increased risk of gynecologi-
cal cancer, with a 40–60% risk of endometrial cancer and
a 5–15% risk of ovarian cancer [3,10-13]. Various rare
tumor types, e.g. cancer in the upper urothelial tract, the
small intestine, gastric cancer, brain tumor and skin
tumors have also been linked to HNPCC, but the life time
risks for these tumors are <5% [10,14-18].
Several features are indicative of HNPCC, e.g. develop-
ment of multiple HNPCC associated cancers in a family,
young age at diagnosis, synchronous and metachronous
tumors and certain morphological characteristics. In order
to facilitate diagnosis and classification of HNPCC, vari-
ous guidelines have been developed. The most widely
used are the Bethesda guidelines aimed at identifying
tumors that should undergo further evaluation for
HNPCC, and the Amsterdam criteria aimed at uniform
classification of HNPCC families [19-21]. Our study
focused on individuals with disease predisposing mis-
match repair (MMR) gene mutations, also referred to as
Lynch syndrome. International criteria for surveillance of
HNPCC families with MMR gene mutations have been
published and adopted by the International Society for
Hereditary Gastrointestinal Tumors [5,6]. These guide-
lines recommend colonoscopy biannually from age 20–
25 and gynecological examinations with transvaginal
ultrasound and endometrial biopsies annually from age
30–35. Whereas colonoscopy surveillance in this high risk
population has been proven cost effective, the value of the
gynecological surveillance remains unclear [22,23].
Indeed, the high risks of endometrial and ovarian cancer
may affirm prophylactic hysterectomy with concomitant
oophorectomy after child bearing age [6,24]. Also, the
value of gastric cancer and upper tract urothelial cancer
surveillance remains unclear, but intervention is recom-
mended from 30–35 years, in families were these tumor
types have occurred [6,25].
At risk individuals in HNPCC families are dependent on
health care for diagnosis and surveillance, but several
studies have suggested that these individuals perceive a
lack of knowledge from health care personnel [1,26-28].
We therefore distributed a questionnaire containing key
statements related to knowledge of cancer risks and sur-
veillance strategies to mutation carriers in HNPCC fami-
lies and to physicians in surgery, gynecology and
oncology, who are likely to diagnose, treat and survey
these families.
Methods
Questionnaire
The questionnaire contained 11 statements related to
colorectal cancer in general (questions 1 and 3), HNPCC
cancer risk (questions 2, 4 and 5), surveillance (questions
6 and 7), heredity (questions 8 and 11) and genetic testing
(questions 9 and 10); the statements were to be marked
"true" or "false" (Additional file 1). Demographic data
were also collected. The questionnaire distributed to the
physicians also contained questions related to risk levels
(<5%, 5–20%, 20–40%, 40–60%, 60–80% and >80%)
for colorectal cancer, endometrial cancer, ovarian cancer,
gastric cancer and upper tract urothelial cancer and initia-
tion age (20–25, 25–35, 35–45 or >45 years) for surveil-
lance programmes of HNPCC associated cancers.
Participants
The questionnaire and a letter of invitation to the study
were mailed to 88 individuals with HNPCC predisposing
MMR gene mutations. All individuals had undergone
genetic counseling and testing at Lund University Hospi-
tal between 1996 and 2008. They had been recommended
surveillance programmes at their local hospitals and those
diagnosed after 2003 also received a HNPCC information
booklet. Data were obtained from 67 (76%) individuals
without differences in age, sex or time since genetic coun-
seling for responders and non responders. Among the
responders the median age was 49 (22–81) years with 38
(57%) being female and 19 (28%) representing index
individuals in their families. Educational level was ele-
mentary school in 27%, high school in 31%, university in
27% and other in 15% of the at risk individuals. The
median time since genetic counseling was 4 (0–12) years
and 28 (42%) had a personal history of cancer.
In total, 103 physicians from 6 departments (2 university
hospitals and 3 regional hospitals) in the southern Swe-
den health care region were invited to participate during
staff meetings. After filling out the questionnaire, the
authors presented updated guidelines for identification,
genetic testing and surveillance of HNPCC. Responses
were obtained from 102 (99%) physicians, with a median
age of 47 (22–64) years and 48 (47%) being female. Spe-
cialization was surgery in 40%, gynecology in 29% and
oncology in 30% of the informants. The physicians
reported median 12 (0–39) years in clinical practise. 72%
worked at regional hospitals and 28% were employed at a
university hospital.BMC Medical Genetics 2009, 10:30 http://www.biomedcentral.com/1471-2350/10/30
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Ethical approval for the study was granted from the Lund
University ethics committee (346/2007).
Statistical analysis
STATA (StataCorp. 2005. Stata Statistical Software: Release
9. College Station, TX: StataCorp LP) was used for the sta-
tistical analyses. For each of the eleven questions, the Chi-
squared test was used for comparison of the fraction of
correct answers among mutation carriers and physicians,
whereas Kruskal-Wallis test was applied to compare the
distribution of correct answers (range 0–11) in two or
more groups. Linear regression was used for multivariate
analysis. Unanswered questions were interpreted as miss-
ing values. All tests were two-tailed and p-values < 0.05
were considered significant.
Results
Key statements among at risk individuals
The median number of correctly answered questions was
9 (3–11) of 11 (Additional file 1). Questions about color-
ectal cancer in general, HNPCC associated cancer risk and
genetic testing had a high number of correct answers.
Questions 3 (individuals not carrying a HNPCC mutation
will never develop colorectal cancer) and 7 (individuals that
carry HNPCC mutations need regular colonoscopies) had the
highest frequencies, 99% and 96%, of correct answers.
Knowledge about risks for other cancer types and mecha-
nisms of inheritance was less accurate; half (52%) of the
mutation carriers marked the risk of inheriting a MMR
mutation as 25% (question 8, correct answer being 50%)
and two thirds (63%) recognized that female family
members are at increased risk of ovarian cancer (question
5). Young age (<57 years), female sex and shorter time
since genetic counseling significantly correlated with bet-
ter results in univariate and multivariate analysis (Table
1). The youngest age group answered 84% of the ques-
tions correctly, compared to 71–72% among individuals
>57 years (p = 0.02; three group comparison). Females
answered 81% of the questions correctly, compared to
71% in males (p = 0.01). Also, time since genetic coun-
seling was significantly associated with the results, with
better knowledge among individuals who underwent
genetic counseling within the last 6 years (p = 0.02; three
group comparison). Sex, age and time since genetic coun-
seling explain 32% of the variability of correct answers (R2
from multivariate analysis). Education, previous cancer
diagnosis and status as index individual did not signifi-
cantly influence the results.
Key statements among physicians
The median number of correctly answered questions
among the physicians was 9 (5–11) (Additional file 1).
Questions about cancer risk, colonoscopies, and genetic
testing (questions 3, 6, 9 and 10) were correctly answered
Table 1: Characteristics of mutation carriers in relation to correct answers
Characteristics Number of individuals Correct answers Kruskal-Wallis Test Multivariate analysis
n = 67 Total (%) p-value p-value*
Overall 67 562 (76%)
Age (22–81) 0.02 0.001
≤ 45 years 25 230 (84%)
46–56 years 21 167 (72%)
≥ 57 years 21 165 (71%)
Sex 0.01 0.002
Female 38 337 (81%)
Male 29 225 (71%)
Education 0.51
Elementary school 17 133 (71%)
High School 21 177 (77%)
University 18 160 (81%)
Other/no data 11 92 (76%)
Index person 0.29
Yes 19 166 (79%)
No 48 396 (75%)
Time since genetic counseling (0–11) 0.08 0.02
≤ 3 years 26 231 (81%)
4–6 years 23 192 (76%)
≥ 7 years 18 139 (70%)
Previous cancer 0.31
Yes 28 230 (75%)
No 39 332 (77%)
*Linear regression model with answers as the dependent variable and age, time since genetic counseling and sex as independent variablesBMC Medical Genetics 2009, 10:30 http://www.biomedcentral.com/1471-2350/10/30
Page 4 of 7
(page number not for citation purposes)
by 90–100% and for most of the statements the results
were similar between family members and physicians.
Compared to family members, physicians significantly
more often gave correct answers to questions 6, 7 and 9
(which related to colonoscopies and tumor tissue for
diagnostic purposes), but scored significantly worse than
the family members on question 8: individuals with
HNPCC will pass the mutated gene on to 25% (1 in 4) of their
children. Only 30% of the physicians indicated that this
was wrong. Regarding the risk of endometrial cancer, 77%
indicated a risk for endometrial cancer and 61% indicated
a risk for ovarian cancer. There were no significant differ-
ences in the outcome in relation to specialization (i.e. sur-
gery, gynecology or oncology), employment at a
university hospital or a regional hospital, sex or age.
Risk and surveillance strategies among physicians
The questions on cancer risk and surveillance posed to the
physicians, demonstrated suboptimal knowledge, but did
not correlate with characteristics such as age, sex and time
in practise. The cumulative cancer risks were correctly
indicated by less than half of the physicians; 45% for
colorectal cancer, 18% for endometrial cancer, 43% for
ovarian cancer, 39% for gastric cancer and 54% for upper
tract urothelial cancer (Figure 1). Only 53% correctly indi-
cated the initiation age for colonoscopies and 38% for
gynecological cancer. Though surveillance for gastric can-
cer and upper tract urothelial cancer remains controver-
sial, current guidelines suggest initiation at age 30–35 in
affected families, whereas the majority indicated a starting
Scatter plot of physicians estimation of the lifetime risk of various HNPCC-associated cancer types Figure 1
Scatter plot of physicians estimation of the lifetime risk of various HNPCC-associated cancer types. The physi-
cians generally underestimated the risk of the common types of HNPCC-associated cancers; with 56% underestimating the risk 
of colorectal cancer and 77% of endometrial cancer. Ovarian cancer was underestimated by 29% and overestimated by 25%. 
The risks of rare tumor types were, on the other hand, generally overestimated; by 41% for upper tract urothelial cancer and 
47% for gastric cancer. For visual purpose, independent random errors, drawn from a uniform distribution on a circle with 
centre (0,0), have been added to the responses.
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age >45 years, which is higher than recommended in any
guideline.
Discussion
After the identification of disease predisposing MMR gene
mutations in the early 1990'ies, genetic testing for
HNPCC was established. Clinical geneticists and genetic
counselors were educated, but the translation of knowl-
edge and implementation among physicians responsible
for diagnostics and surveillance has in many instances
been difficult [27-29]. An increasing number of healthy at
risk individuals now undergo genetic testing and though
not formally patients, these individuals are dependent on
health care for early cancer prevention. Individuals in
HNPCC families often have experience of cancer, if not
personal, perhaps in close family members. Their experi-
ences and the vast amount of information available, not
least on the internet, make them well educated with exten-
sive knowledge about HNPCC. They thereby provide a
challenge to the responsible physician and previous stud-
ies suggest that they perceive a lack of professional knowl-
edge when discussing risks and preventive strategies with
health care personnel [30].
The key statements used to assess knowledge about
HNPCC revealed surprisingly similar results for at risk
individuals and physicians (Additional file 1). Physicians
scored significantly better on questions related to surveil-
lance and diagnostics (questions 6, 7 and 9). Both groups
revealed weaknesses related to mechanisms of inheritance
as exemplified by 70% of the physicians answering that "1
of 4 children will inherit the mutated gene" (which is
wrong since this figure applies to recessive disorders and
the correct answer is 50% in dominantly inherited disor-
ders). Only 30% of the physicians and 52% of the family
members correctly answered this statement, and the result
was indeed significantly better in the family members.
Also, 25% of family members and physicians alike
answered that male inheritance is more common, which
is wrong since no sex difference applies to autosomal
inherited disorders. The demonstration of equal and in
some instances better knowledge among members of
hereditary cancer families, than among physicians respon-
sible for the management of at risk individuals, is likely to
influence trust and satisfaction. These findings are in line
with indications of dissatisfaction on behalf of the
patients and likely to reflect frustration among physicians.
Since experience among physicians did not influence the
result, education in genetic medicine probably needs to be
improved during medical education.
Two thirds of physicians and family members alike failed
to recognize the increased risk of ovarian cancer in
HNPCC, which may be related to the more recent focus
on the 10–15% risk of this tumor type in female carriers.
This issue, however, reflects the need to establish ways to
reach out with new information to families and responsi-
ble physicians. In order to optimize management of these
families, reassurance that the individual has understood
the information and distribution of printed information
which can be brought home and shared with other family
members seem efficient. Among the mutation carriers,
older individuals and males had a significantly lower
number of correct scores, which may indicate that these
groups need to receive information in other ways. There
was also a trend for higher scores in individuals who had
undergone genetic counseling within 6 years compared to
those counseled a longer time ago, which may imply a
need for information update; many family members ask
for possibilities to learn about recent research findings
related to HNPCC.
The additional questions posed to the physicians regard-
ing surveillance programmes demonstrated that 3 out of 4
estimated a later starting age and a longer time between
the examinations than recommended [5,6]. Surveillance
for colorectal cancer is based on consistent results from
several well designed and well performed studies, whereas
there is yet insufficient evidence to support the other sur-
veillance programmes for gynecological cancer, upper
tract urothelial cancer and gastric cancer. Knowledge
about the evidence and recommendations according to
current international guidelines is central for physicians
responsible for diagnosis and clinical management of
HNPCC. Though we cannot exclude poorer results in the
health care region where the data were collected, several
recent studies demonstrate insufficient knowledge about
hereditary cancer among physicians [27,29,31]. A com-
prehensive evaluation of knowledge and management of
hereditary cancer, including different regions and health
care systems, is called for in order to determine strategies
for improved education which may lead to refined future
diagnostics and management of HNPCC family members.
Conclusion
In summary, this study reveals weaknesses in HNPCC
knowledge, particularly among physicians. By tradition,
the medical perspective dominates and decides on rele-
vant and evidence based interventions. When a majority
of the physicians misinterpret hereditary mechanisms,
underestimate the risk of cancer, and fail to recognize
HNPCC associated tumor types the likelihood of misin-
formation is high. Physician behaviour may also influ-
ence patient adherence to surveillance programmes, and
our findings strongly suggest that improved education in
genetic medicine is needed for physicians responsible for
diagnosis and management of the growing number of
individuals at increased risk of cancer [31-33].BMC Medical Genetics 2009, 10:30 http://www.biomedcentral.com/1471-2350/10/30
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